These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26787899)

  • 1. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
    Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
    Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
    Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
    Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.
    van Keimpema M; Grüneberg LJ; Mokry M; van Boxtel R; Koster J; Coffer PJ; Pals ST; Spaargaren M
    Blood; 2014 Nov; 124(23):3431-40. PubMed ID: 25267198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
    Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
    Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S1PR2 deficiency in DLBCL: a FOXy connection.
    Baldari CT
    Blood; 2016 Mar; 127(11):1380-1. PubMed ID: 26989186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
    Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
    Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
    Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
    Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
    Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.
    Wlodarska I; Veyt E; De Paepe P; Vandenberghe P; Nooijen P; Theate I; Michaux L; Sagaert X; Marynen P; Hagemeijer A; De Wolf-Peeters C
    Leukemia; 2005 Aug; 19(8):1299-305. PubMed ID: 15944719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
    Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.
    Walker MP; Stopford CM; Cederlund M; Fang F; Jahn C; Rabinowitz AD; Goldfarb D; Graham DM; Yan F; Deal AM; Fedoriw Y; Richards KL; Davis IJ; Weidinger G; Damania B; Major MB
    Sci Signal; 2015 Feb; 8(362):ra12. PubMed ID: 25650440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.